- Atrial fibrillation (AF) is a worldwide health issue affecting millions and increases significantly with age. It significantly impacts quality of life and places a considerable economic strain on healthcare systems
- Mitochondrial dysfunction plays a critical role in the development of AF, affecting energy production, cellular ion balance, and oxidative stress levels. This dysfunction contributes to both electrical and structural remodeling of the heart
- Certain existing medications, especially those used for diabetes management such as DPP-4 inhibitors and SGLT2 inhibitors, show potential in improving mitochondrial function and possibly reducing AF risk
- Emerging therapies focusing on mitochondrial function, including new drugs and gene therapies, are being developed and may offer new strategies for AF prevention and treatment in the future
- Promoting mitochondrial health through lifestyle choices and discussing mitochondrial-targeted therapies with healthcare providers may help reduce AF risk, particularly as you age.
Atrial fibrillation (AF) is a silent epidemic that is gradually affecting people worldwide. As the most prevalent type of irregular heart rhythm, it impacts millions globally, with prevalence estimates between 1% and 2% in the U.S. general population.
In AF, your heart’s electrical system malfunctions, leading to irregular and sometimes rapid rhythms. This significantly increases your stroke risk—up to five times higher. The reason is that your irregular heartbeat can cause blood to pool and clot in your heart, which can then travel to your brain.
What’s particularly concerning is the dramatic increase in AF risk with age. While it’s relatively rare in younger adults, affecting only about 0.1% of those under 55, the prevalence is estimated at 6.4% for those aged 65 to 69, and 28.5% for those over 85.
However, AF isn’t just an issue for the elderly. In some cases, it can strike at a much younger age due to genetic factors or congenital heart defects. For these younger patients, the cause is often found in the pulmonary veins, where abnormal electrical activity can trigger AF episodes. While this type of AF, known as paroxysmal AF, can often be successfully treated with pulmonary vein ablation, the situation is different for older patients.
As you age, your heart tissue naturally degenerates, and various health conditions can affect your heart’s structure and metabolism. These factors create an environment conducive to persistent or permanent AF, which is much harder to treat effectively.
The impact of AF extends beyond an irregular heartbeat, significantly diminishing your quality of life, increasing your risk of other health problems, and even shortening your lifespan.
The economic burden is also substantial. In the United States alone, the cost of AF treatment was a staggering $6.65 billion in 2005, including $2.93 billion (44%) for hospitalizations. In a privately insured U.S. population, the direct annual cost of AF was estimated at $15,553 per patient, which was $12,349 more than enrollees without AF.
These costs have only increased with the introduction of newer anticoagulant medications. As the population in developed countries continues to age, the number of people affected by AF is set to rise dramatically. This looming health crisis underscores the urgent need for a better understanding of AF development and improved strategies for prevention and treatment.
The Function of Mitochondria in AF
At the core of this intricate condition lies a fascinating and often overlooked element: your mitochondria. These small powerhouses within your cells have been linked to the development of AF since the 1970s. Mitochondria are abundant in metabolically active cells like cardiomyocytes, the specialized muscle cells of your heart.
Their primary function is to generate adenosine 5′-triphosphate (ATP), the energy currency that powers nearly all cellular processes, including the mechanical work of your heartbeat and the intricate ion dance that keeps your heart’s electrical system in rhythm.
When AF begins, it places significant stress on your heart cells. In the early stages of paroxysmal or short-lasting persistent AF, your mitochondria attempt to maintain ATP production. Over time, however, this production begins to falter, indicating mitochondrial dysfunction. The consequences of this energy deficit are extensive.
With reduced ATP availability, all energy-dependent processes in your heart cells begin to suffer. The delicate balance of ions inside and outside your cells is disrupted, enzymatic reactions slow down, and the very contraction and relaxation of your heart muscle is compromised.
Your cells, in dire need of energy, start to rely more heavily on glycolysis, a less efficient form of energy production that occurs in the cell’s cytoplasm rather than in the mitochondria. This shift towards glycolysis and increased lactate production is reminiscent of the Warburg effect observed in rapidly growing tumors. It’s a sign that your heart cells are under severe metabolic stress.
This stress activates a cellular energy sensor known as adenosine monophosphate protein kinase (AMPK). When ATP levels drop and AMP levels rise, AMPK springs into action, redirecting metabolic pathways towards glycolysis and halting energy-consuming anabolic processes.
However, AMPK’s influence extends beyond metabolism. It can also affect ion channels in your heart cells, including the ATP-sensitive potassium channel and the slow inward calcium channel. These changes alter the electrical properties of your heart cells, potentially exacerbating the arrhythmia. Intriguingly, AMPK activation is observed in intermittent AF but not in long-lasting AF, suggesting it may be a compensatory response to the initial metabolic stress induced by the arrhythmia.
Mitochondrial Structure Changes in AF
Regarding structure, mitochondria in AF-affected heart tissue exhibit significant changes. In animal models of persistent AF, researchers have observed initial degradation of myofibrils (the contractile units of heart muscle) and accumulation of glycogen.
This is followed by elongation of mitochondria and alterations in the orientation of their internal folded membranes known as cristae. In mice with AF and heart failure, the mitochondria in atrial heart cells show even more severe damage, including swelling of the mitochondrial matrix and disruption of both inner and outer mitochondrial membranes. These structural changes are directly linked to decreased ATP production.
Human studies have also revealed mitochondrial abnormalities in AF. Atrial tissue samples from patients with AF show an increased number of mitochondria, often with altered shapes. Some studies have found swollen mitochondria with partial or complete disruption of their internal structure. These changes appear to be related to calcium overload in the cells, as they can be prevented by calcium channel blockers.
Mitochondrial Biogenesis Is Disrupted in AF
The process of mitochondrial biogenesis — the creation of new mitochondria — is a complex biological process that controls organelle self-renewal and the maintenance of mitochondrial DNA, ensuring cellular homeostasis. This process involves the coordinated action of numerous regulatory proteins, most of which are encoded by nuclear DNA, with a few key players encoded by mitochondrial DNA.
The master regulator of mitochondrial biogenesis is a protein called PGC-1α (peroxisome proliferator-activated receptor-γ coactivator 1-α). Under normal conditions, high energy demand increases the expression of PGC-1α, stimulating the production of new mitochondria.
As mentioned, in atrial fibrillation (AF), there is evidence of mitochondrial dysfunction, characterized by both functional and morphological changes. Studies have revealed mitochondrial ultrastructural abnormalities in human AF patients, including modifications in shape, volume, and remodeling of the cristae ultrastructure in atrial cardiomyocytes.
Research has also shown that mitochondrial DNA damage occurs in human AF. Initial calcium overload and chronic high oxidative stress levels in fibrillating atria may explain the rapid damage to mitochondrial DNA in human AF. Not surprisingly, improving mitochondrial function has also shown promise in reducing AF susceptibility.
Current Drug Treatments and Beneficial Supplements
Given the crucial role of mitochondrial dysfunction in AF, there’s growing interest in pharmacological interventions that can enhance mitochondrial function and potentially prevent or treat AF. Several classes of drugs, some already used for other conditions like diabetes, show promise in this area.
Dipeptidyl peptidase-4 (DPP-4) inhibitors, a class of drugs used to treat Type 2 diabetes, have shown potential in reducing AF risk. These drugs work by increasing levels of incretin hormones, which stimulate insulin release and inhibit glucagon. However, their benefits extend beyond blood sugar control. In heart cells, DPP-4 inhibitors can attenuate oxidative stress and improve mitochondrial function.
Ubiquinone, also known as Coenzyme Q10, is another compound that has gained attention for its potential role in AF prevention. This naturally occurring substance is an important cofactor in the mitochondrial electron transport chain and a potent antioxidant. Levels of CoQ10 in the heart can decrease with age, statin use, or due to genetic factors.
Some studies have shown that CoQ10 supplementation can improve mitochondrial respiratory function and reduce oxidative stress, and in patients with heart failure, CoQ10 treatment has been shown to significantly reduce major adverse cardiovascular events and lower the death rate.
While there is no direct evidence that CoQ10 improves AF, it seems reasonable to assume that it might, and its good safety profile makes it an interesting candidate for further research as an adjuvant therapy in certain AF risk situations.
Fibrates, which are used to treat high triglyceride levels, may also have a role in AF prevention through their effects on mitochondrial function. These drugs activate PPARα, which can influence mitochondrial function through the PPARα/PGC-1α pathway. Animal studies have shown that fibrates can reverse some of the metabolic and electrical remodeling associated with AF.
While there’s some evidence that lipid-lowering medications, including fibrates, may be associated with a lower prevalence of AF in certain patient populations, the clinical benefits for AF outcomes have not been thoroughly evaluated.
While these existing medications show promise, researchers are also developing new drugs specifically targeting mitochondrial function. One such approach is a synthetic combination of four amino acids (a tetrapeptide) called elamipretide, which is designed to improve mitochondrial energetics and reduce ROS generation by stabilizing the mitochondrial membrane.
Initial results in heart failure were promising, showing improvements in mitochondrial function and left ventricular volumes. However, always consult with your integrated medicine doctor before taking anything